T1	Participants 63 99	postoperative rectal cancer patients
T2	Participants 319 355	postoperative rectal cancer patients
T3	Participants 435 563	Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin
T4	Participants 674 711	Two hundred and twenty-eight patients